<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642979</url>
  </required_header>
  <id_info>
    <org_study_id>PNH-2012</org_study_id>
    <nct_id>NCT01642979</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <acronym>PNH-2012</acronym>
  <official_title>Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic anemia,this study is
      designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in
      patients with classic paroxysmal nocturnal hemoglobinuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of the hematopoietic
      stem cell characterized by intravascular hemolysis, hemoglobinuria, anemia, and thrombosis,
      Patients may be at high risk of thrombosis and may develop bone marrow failure or aplastic
      anemia, with low white blood cell and platelet counts,because the manifestation and
      pathologic processes are complicate,the treatment is very difficult,this study is designed to
      evaluate the safety and efficacy of Levamisole combined with cyclosporine A in patients with
      classic paroxysmal nocturnal hemoglobinuria
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group in complete or partial remission</measure>
    <time_frame>6 months</time_frame>
    <description>she got blood transfusion-independent,the hemoglobin became higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Hemoglobinuria</condition>
  <condition>Hemoglobinuria, Paroxysmal</condition>
  <condition>Proteinuria</condition>
  <condition>Urination Disorders</condition>
  <condition>Thrombosis</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Aplastic Anemia,</condition>
  <condition>Anemia, Hemolytic</condition>
  <arm_group>
    <arm_group_label>Levamisole+cyclosporin A+Glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levamisole+cyclosporin A+Glucocorticoids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyclosporin A+Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclosporin A+Glucocorticoids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole+cyclosporin A+Glucocorticoids</intervention_name>
    <description>Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)</description>
    <arm_group_label>Levamisole+cyclosporin A+Glucocorticoids</arm_group_label>
    <other_name>Levamisole</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporin A+Glucocorticoids</intervention_name>
    <description>cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)</description>
    <arm_group_label>cyclosporin A+Glucocorticoids</arm_group_label>
    <other_name>cyclosporin A</other_name>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Glucocorticoids 0.5-1mg/kg every day(prednisone)</description>
    <arm_group_label>Glucocorticoids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical and biochemical signs of classic Paroxysmal Nocturnal Hemoglobinuria

          2. Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry
             data

          3. patient should complete levamisole study for at least half a year

        Exclusion Criteria:

          1. Active infection which requires antibiotic treatment

          2. Pregnant or lactating women

          3. Epilepsy and mental illness

          4. Kidney and liver function abnormal

          5. patient who terminate ealy from levamisole study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yizhou zheng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital,</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.chinablood.com.cn</url>
    <description>CBD</description>
  </link>
  <reference>
    <citation>Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Soci√© G; International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 Dec 1;106(12):3699-709. Epub 2005 Jul 28. Review.</citation>
    <PMID>16051736</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>January 1, 2013</last_update_submitted>
  <last_update_submitted_qc>January 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yizhou Zheng</investigator_full_name>
    <investigator_title>Vice director of the therapeutic centre of anemic diseases</investigator_title>
  </responsible_party>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>bone marrow failure</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Levamisole</keyword>
  <keyword>cyclosporine A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Urination Disorders</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

